Testing Menu

New discoveries are increasing the number of biomarker/drug associations at an unprecedented rate. It is more important than ever for cancer patients to have comprehensive molecular testing on their tumors. 

Comprehensive Tumor Profiling

Caris molecular profiling utilizes a comprehensive approach to assess DNA, RNA and proteins to reveal a molecular blueprint to guide more precise and individualized treatment decisions from among 60+ FDA-approved therapies.
icon_DNA

DNA

Whole Exome Sequencing
(Mutations, Indels & Copy Number Alterations)

icon_RNA

RNA

Whole Transcriptome Sequencing
(Fusions & Variant Transcripts)

icon_Protein

Protein

Immunohistochemistry
(Tumor-expressed antigens)

Technical Specifications

Sufficient tumor content (>20% tumor nuclei) must be present to complete all analysis. If you have questions, please contact Customer Support at (888) 979-8669.

FFPE/SLIDE TISSUE

Tumor content: >20% tumor nuclei


Paraffin Block (Preferred)

Formalin fixed tissue block (including core-needle biopsies, fine-needle aspirates or malignant fluid)


Unstained Slides

25 slides

FRESH TISSUE

10% neutral buffered formalin


Four to six (4-6) biopsies with 18 gauge needle preferred


Six to ten (6-10) biopsies with 22 needle accepted

MI Profile Specs


Approach
Multi-Omic Biomarker Analysis


Biological Coverage
DNA  RNA  Protein


Variant Coverage
Somatic


Technology
NGS (WES & WTS)  IHC  ISH  PyroSeq


Genes | Depth/Read
22,000 | 500-1000x WES/60M WTS


Whole Exome Sequencing (WES) DNA
SNV  INDEL  CNA


Whole Transcriptome Sequencing (WTS) RNA
Fusion  Variant Transcript


Genomic Signatures
MSI  TMB  LOH


Other

HLA Genotype*


Enrichment Method
Microdissection


Result Rate
>95%


Turnaround Time
10-14 Days


Specimen Quantity
20% Tumor (NGS) | 1 Slide per IHC/ISH

*Not available in New York state.

Biomarker Analysis by Tumor Type

The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted.

Download Profile Menu for US and Intl PDF >

Download Profile Menu for New York State PDF >

Download Profile Menu for Europe PDF >

Looking for a Specific Gene?

Use our full gene search to verify that it is included in Caris profiling, or browse the list of genes most commonly associated with cancer.

Search Genes >

General Profile Menu (see above links for market specific menus)

All Biomarker Analysis includes:

Whole Exome Sequencing (WES)

DNA
Genomic
Signatures
Others
Point Mutations
Indels
Copy Number Alterations
HPV 16 and 18
MSI
TMB
LOH
HLA*
*Not available in New York state

Whole Transcriptome Sequencing (WTS)

RNA
Fusion Analysis
Variant Transcripts

Additional Testing:

Select tumor type to see specific tests to be performed.

Tumor Type:
No tumor selected

Additional Information:

  • Caris applies the appropriate tumor-specific customizations standard with every order.
  • In certain instances, some biomarkers or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
  • For PD-L1 IHC testing, Dako antibodies 22c3, 28-8 and antibodies SP-142 and SP263 are used as appropriate.
  • For certain patients, HER2 testing is performed by Chromogenic in situ Hybridization, in addition to Next-Generation Sequencing.

REFLEX TESTING MENU >

Order a test

Place an order for your customized MI Profile Report.